Coya Therapeutics' COYA 302 ALS Trial Accepted by NEALS as a NEALS-Affiliated Trial
1. COYA 302 trial selected by NEALS, enhancing development for ALS treatments. 2. FDA accepted COYA 302 IND; Phase 2 study starts Q4 2025. 3. Presentation of COYA 302 study during NEALS Educational Webinar scheduled for September 2025. 4. Trial supports innovative approach to ALS treatment through regulatory T cell enhancement. 5. Coya's commitment to ALS treatment advancement emphasized by discovery and research partnerships.